



# Classical fever of unknown origin in 21 countries with different economic development: an international ID-IRI study

Hakan Erdem<sup>1</sup> · Magdalena Baymakova<sup>2</sup> · Sevil Alkan<sup>3</sup> · Amel Letaief<sup>4</sup> · Wissal Ben Yahia<sup>4</sup> · Farouq Dayyab<sup>5</sup> · Entela Kolovani<sup>6</sup> · Svtjetlana Grgic<sup>7</sup> · Federica Cosentino<sup>8</sup> · Imran Hasanoglu<sup>9</sup> · Reham Khedr<sup>10</sup> · Andrea Marino<sup>8</sup> · Abdullah Umud Pekok<sup>11</sup> · Fatma Eser<sup>9</sup> · Jurica Arapovic<sup>7</sup> · Hatice Rahmet Guner<sup>9</sup> · Ionela-Larisa Miftode<sup>12</sup> · Kostadin Poposki<sup>13</sup> · Gamze Sanlidag<sup>14</sup> · Alper Tahmaz<sup>15</sup> · Oguz Resat Sipahi<sup>14</sup> · Egidia Gabriela Miftode<sup>12</sup> · Serkan Oncu<sup>16</sup> · Meliha Cagla-Sonmezer<sup>17</sup> · Syam Kumar Addepalli<sup>18</sup> · Ilad Alavi Darazam<sup>19</sup> · Hema Prakash Kumari<sup>20</sup> · Meliha Meriç Koc<sup>21</sup> · Meela Ranjith Kumar<sup>22</sup> · Suresh Babu Sayana<sup>23</sup> · Ahmed Ashraf Wegdan<sup>24</sup> · Fatma Amer<sup>25</sup> · Mehmet Resat Ceylan<sup>26</sup> · Amani El-Kholy<sup>27</sup> · Taylan Onder<sup>3</sup> · Hamed Azhdari Tehrani<sup>28</sup> · Atousa Hakamifard<sup>19</sup> · Bircan Kayaaslan<sup>9</sup> · Ghaydaa Shehata<sup>29</sup> · Hulya Caskurlu<sup>30</sup> · Nagwa Mostafa El-Sayed<sup>31</sup> · Seyed Erfan Mortazavi<sup>19</sup> · Mohammad Pourali<sup>19</sup> · Umran Elbahr<sup>32</sup> · Sholpan Kulzhanova<sup>33</sup> · Tarkan Yetisyigit<sup>34</sup> · Sahar Ahmed Saad<sup>35</sup> · Yasemin Cag<sup>30</sup> · Gulden Eser-Karlidag<sup>36</sup> · Natalia Pshenichnaya<sup>37</sup> · Maya Belitova<sup>38</sup> · Nasim Akhtar<sup>39</sup> · Fahad Al-Majid<sup>40</sup> · Muge Ayhan<sup>9</sup> · Mumtaz Ali Khan<sup>41</sup> · Massimiliano Lanzafame<sup>42</sup> · Mateja Jankovic Makek<sup>43</sup> · Emmanuel Nsutebu<sup>44</sup> · Antonio Cascio<sup>45</sup> · Emine Kubra Dindar-Demiray<sup>46</sup> · Emine Unal Evren<sup>47</sup> · Rama Kalas<sup>48</sup> · Ayşe Kaya Kalem<sup>9</sup> · Rusmir Baljić<sup>49</sup> · Aamer Ikram<sup>50</sup> · Selcuk Kaya<sup>51</sup> · Anna Liskova<sup>52</sup> · Balint Gergely Szabo<sup>53</sup> · Bilal Ahmad Rahimi<sup>54</sup> · Esmeray Mutlu-Yilmaz<sup>55</sup> · Alper Sener<sup>3</sup> · Jordi Rello<sup>56,57</sup>

Received: 4 November 2022 / Accepted: 3 February 2023

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023

## Abstract

Fever of unknown origin (FUO) is a serious challenge for physicians. The aim of the present study was to consider epidemiology and dynamics of FUO in countries with different economic development. The data of FUO patients hospitalized/followed between 1st July 2016 and 1st July 2021 were collected retrospectively and submitted from referral centers in 21 countries through ID-IRI clinical research platform. The countries were categorized into developing (low-income (LI) and lower middle-income (LMI) economies) and developed countries (upper middle-income (UMI) and high-income (HI) economies). This research included 788 patients. FUO diagnoses were as follows: infections (51.6%;  $n=407$ ), neoplasms (11.4%,  $n=90$ ), collagen vascular disorders (9.3%,  $n=73$ ), undiagnosed (20.1%,  $n=158$ ), miscellaneous diseases (7.7%,  $n=60$ ). The most common infections were tuberculosis ( $n=45$ , 5.7%), brucellosis ( $n=39$ , 4.9%), rickettsiosis ( $n=23$ , 2.9%), HIV infection ( $n=20$ , 2.5%), and typhoid fever ( $n=13$ , 1.6%). Cardiovascular infections ( $n=56$ , 7.1%) were the most common infectious syndromes. Only collagen vascular disorders were reported significantly more from developed countries ( $RR=2.00$ , 95% CI: 1.19–3.38). FUO had similar characteristics in LI/LMI and UMI/HI countries including the portion of undiagnosed cases ( $OR$ , 95% CI; 0.87 (0.65–1.15)), death attributed to FUO ( $RR=0.87$ , 95% CI: 0.65–1.15,  $p$ -value = 0.3355), and the mean duration until diagnosis ( $p=0.9663$ ). Various aspects of FUO cannot be determined by the economic development solely. Other development indices can be considered in future analyses. Physicians in different countries should be equally prepared for FUO patients.

**Keywords** Economic development · Fever · Fever of unknown origin · FUO · ID-IRI

✉ Hakan Erdem

✉ Yasemin Cag  
yasemncag@yahoo.com

Extended author information available on the last page of the article

## Introduction

Fever of unknown origin (FUO) is a clinical and diagnostic challenge in routine medical practice and the potential causes of FUO may involve more than 200 diseases [1, 2]. Apart

from diarrheal diseases, respiratory infections, and skin lesions, FUO is one of the most common health problems in travelers [3, 4]. In 1961, Petersdorf and Beeson published the first fundamental research on FUO. In 1991, Durack and Street revised previous definition of FUO and suggested that the diagnostic period should be as short as three days with the improving diagnostic capacities of the hospitals [5].

Although there are economic inequalities, social and political tensions around the world, lifesaving technologies have improved the diagnostic capacity greatly. There has been an increase in the life expectancy leading to aging of populations, which is more visible in countries with high economic and social development compared to countries with limited resources [6]. On the other hand, lifesaving technologies, innovation, and ongoing researches have improved the quality of human life greatly. There has been a recent increase in the life expectancy leading to aging of populations, which is more visible in countries with high economic and social development compared to the countries with limited resources. Accordingly, chronic diseases like hypertension, diabetes, and malignant diseases increased with advancing age [7] and this trend has the potential to result in more FUO cases in the community, particularly the elders. Thus, we aimed to show the alterations in FUO epidemiology by including the economic statuses of the countries. To the best of our knowledge, no such research has been conducted.

## Materials and methods

The diagnoses of diseases were established in this case series according to the common concepts elsewhere. FUO was defined as follows: (a) febrile illness of more than 3 weeks; (b) fever higher than 38.3 °C on several occasions; (c) absence of diagnosis after three inpatient days or three outpatient visits to physician.

### The inclusion criteria:

- a) Adults > 18 years of age
- b) Patients hospitalized/followed between 1st July 2016 – 1st July 2021
- c) Patients with the main clinical symptom – fever

### The exclusion criteria:

- a) Known immunodeficiency
- b) Pregnancy

## Data collection and participants

This study was performed through ID-IRI international clinical research platform (<https://infectdisiri.com/>). ID-IRI has members worldwide as clinical researchers and they voluntarily join ID-IRI research projects. Demographic parameters, clinical presentation, laboratory results, and clinical outcomes of all participants were obtained from electronic medical records retrospectively. Axillary temperature was measured in all study participants. For the thermometerization process, it used validated and licensed thermometers approved by the referral medical centers (hospitals) which included in this research. The participants in the study were divided in two groups on admission: “Non-late elderly” — persons aged 75 years and below; and “Late elderly” — persons over 75 years of age [8].

## Stratification of the economic status

Countries were stratified as “low-income economies” — Gross National Income (GNI) per capita of US \$1045 or less; “lower middle-income economies” — GNI per capita between US \$1046 and \$4095; “upper middle-income economies” — GNI per capita between US \$4096 and \$12,695; and “high-income economies” — GNI per capita of \$12,696 or more [9]. Countries where participating centers were located were categorized as lower income (LI) (Afghanistan), lower-middle income (LMI) (Egypt, India, Iran, Pakistan, Tunisia), upper-middle income (UMI) (Albania, Bosnia and Herzegovina, Bulgaria, Kazakhstan, North Macedonia, Romania, Russian Federation, Turkey), and high income (HI) countries (Croatia, Cyprus, Hungary, Italy, Saudi Arabia, Slovakia, United Arab Emirates) (Fig. 1).

## Statistical analysis

Statistical analysis was performed using descriptive statistics to present results as frequencies and percentages. To present quantitative variables, we obtained median and interquartile ranges or mean and standard deviations as appropriate. One-way analysis of variance was used to examine whether the mean values of inflammatory markers differ across various fever of unknown origin diagnoses. Relative risks and 95% confidence intervals were obtained to determine associations. *p*-value of less than 0.05 was statistically significant.



**Fig. 1** The countries where participant centers are located

## Ethics

The present survey was performed in accordance with the ethical principles and recommendations of the Declaration of Helsinki (June 1964, last revision in October 2013). All medical procedures in this research were performed according to the national legislation of the country in which the medical center (hospital) is located. The ethical approval of the study was taken from The Ethical Counsel of Istanbul Medeniyet University, Faculty of Medicine, Istanbul (4 August 2021/0411).

## Results

We included 788 patients to our survey. The median (IQR) duration until diagnosis after hospital admission was 12 (8–21) days. The mean age of the patients was  $46.8 \pm 18.1$  years and 345 (43.8%) were females, 744 (94.4%) were adults (18–75 years), and 44 (5.6) were late elders ( $\geq 76$  years). Economically, 74 (9.4%) patients were from HI, 1 (0.1%) was from LI, 297 (37.7%) were from LMI, and 416 (52.8%) were from UMI countries.

### Distribution of the cases by the countries

The data of patients were submitted from 21 countries: Afghanistan ( $n = 1$ ; 0.1%), Albania ( $n = 31$ ; 3.9%), Bosnia and Herzegovina ( $n = 55$ ; 6.9%), Bulgaria ( $n = 37$ ; 4.7%), Croatia ( $n = 3$ ; 0.4%), Cyprus ( $n = 2$ ; 0.3%), Egypt ( $n = 75$ ;


9.5%), Hungary ( $n = 1$ ; 0.1%), India ( $n = 50$ ; 6.3%), Iran ( $n = 50$ ; 6.3%), Italy ( $n = 59$ ; 7.5%), Kazakhstan ( $n = 5$ ; 0.6%), North Macedonia ( $n = 18$ ; 2.3%), Pakistan ( $n = 7$ ; 0.9%), Romania ( $n = 33$ ; 4.3%), Russia ( $n = 5$ ; 0.6%), Saudi Arabia ( $n = 3$ ; 0.4%), Slovakia ( $n = 1$ ; 0.1%), Tunisia ( $n = 117$ ; 14.8%), Turkey ( $n = 232$ ; 29.3%), and United Arab Emirates ( $n = 5$ ; 0.6%).

### A. Reasons for FUO

The distribution of FUO diagnoses were as follows: infections ( $n = 407$ , 51.6%), neoplasms ( $n = 90$ , 11.4%), collagen vascular disorders ( $n = 73$ , 9.3%), undiagnosed ( $n = 158$ , 20.1%), miscellaneous diseases ( $n = 60$ , 7.7%) (Fig. 2).

#### I. Infections ( $n = 407$ )

- a) **Zoonoses** ( $n = 88$ ): (Brucellosis ( $n = 39$ ) {no organ involvement ( $n = 31$ ); prostatitis ( $n = 1$ ); sacroiliitis ( $n = 1$ ); spondylodiscitis ( $n = 6$ )}, rickettsiosis ( $n = 23$ ) (Q fever ( $n = 11$ ); untyped ( $n = 6$ ); Marseilles fever ( $n = 4$ ); *Rickettsia conorii* infection ( $n = 2$ )), lyme disease ( $n = 5$ ), visceral leishmaniasis ( $n = 4$ ), CCHFV ( $n = 3$ ), toxoplasmosis ( $n = 3$ ), cat scratch disease ( $n = 2$ ), malaria ( $n = 2$ ), hantavirus pulmonary syndrome ( $n = 1$ ), hydatid disease (liver,  $n = 1$ ), toxocariasis ( $n = 2$ ), tularemia ( $n = 1$ ), typhus ( $n = 1$ ), WNV infection ( $n = 1$ )).
- b) **Returning travelers:** Two Malaria cases returning from Africa to Türkiye (*Plasmodium ovale*) and Romania (*P.*

**Fig. 2** Distribution of FUO diagnoses

*falciparum*) (0.5% of all infections) were associated to international travel.

- c) **Cardiovascular infections** ( $n = 56$ ): native valve endocarditis ( $n = 44$ ), brucellar endocarditis ( $n = 3$ ), pericarditis ( $n = 3$ ), prosthetic valve endocarditis ( $n = 2$ ), myocarditis ( $n = 2$ ), pace-maker endocarditis ( $n = 1$ ), culture negative endocarditis ( $n = 1$ ).
- d) **Respiratory tract infections** ( $n = 36$ ): (pneumonia ( $n = 18$ ); bronchopneumonia ( $n = 3$ ); atypical pneumonia (*Mycoplasma pneumoniae*  $n = 3$ ; *Chlamydia pneumoniae*  $n = 1$ ; *Chlamydia psittaci*  $n = 1$ ; untyped  $n = 2$ ); empyema ( $n = 2$ ); actinomycosis ( $n = 1$ ); *Pneumocystis jiroveci* pneumonia ( $n = 1$ ); pulmonary tuberculosis ( $n = 1$ ); maxillary sinusitis ( $n = 1$ ); atypical measles ( $n = 1$ ); obliterating bronchiolitis ( $n = 1$ ); tonsillopharyngitis ( $n = 1$ )).
- e) **Urogenital infections** ( $n = 35$ ): urosepsis ( $n = 11$ ); lower urinary tract infections ( $n = 11$ ); pyelonephritis ( $n = 8$ ); chronic cystitis ( $n = 1$ , *Ureaplasma urealyticum*); hydrolyonephrosis ( $n = 1$ ); pelvic infection ( $n = 1$ ); perinephritis ( $n = 1$ ), gonorrhea ( $n = 1$ ).
- f) **Intestinal infections** ( $n = 23$ ): typhoid fever ( $n = 13$ ), neutropenic colitis ( $n = 3$ ), *Clostridioides difficile* colitis ( $n = 2$ ), enterocolitis, untyped ( $n = 1$ ), diverticulitis ( $n = 2$ ), colon perforation ( $n = 1$ ), typhlitis ( $n = 1$ ).
- g) **Viral infections** ( $n = 39$ ): (HIV/AIDS ( $n = 20$ ); EBV infection ( $n = 8$ ); CMV infection ( $n = 7$ ); COVID-19 ( $n = 2$ ); parvovirus infection ( $n = 1$ ); retroviral infection ( $n = 1$ )).
- h) **Tuberculosis** ( $n = 45$ ): (pulmonary ( $n = 15$ ); miliary ( $n = 11$ ); lymphadenitis ( $n = 7$ ); peritoneal ( $n = 4$ ); pleurisy ( $n = 3$ ); hepatic ( $n = 2$ ); intestinal ( $n = 2$ ); mediastinal ( $n = 1$ )),
- i) **Central nervous system infections** ( $n = 17$ ): meningitis, untyped ( $n = 7$ ); tuberculous meningitis ( $n = 1$ ); brucellar meningitis ( $n = 1$ ); thoraco-lumbar myelitis ( $n = 1$ ); HIV encephalitis ( $n = 1$ ); ventriculoperitoneal shunt infection ( $n = 1$ ); viral encephalitis (untyped ( $n = 3$ ); Toscana virus ( $n = 1$ )), cryptococcal meningitis ( $n = 1$ ).
- j) **Bacteremia of unidentified origin** ( $n = 10$ ): *Staphylococcus aureus* ( $n = 4$ ); *Klebsiella pneumoniae* ( $n = 2$ ); *Enterococcus faecalis* ( $n = 1$ ); *Streptococcus constellatus* ( $n = 1$ ); *Pseudomonas aeruginosa* ( $n = 1$ ); *Acinetobacter baumannii* ( $n = 1$ ); *Escherichia coli* ( $n = 1$ ).
- k) **Bone and joint infections** ( $n = 9$ ): (spondylodiscitis ( $n = 7$ ); skull base osteomyelitis ( $n = 1$ ); sacroiliitis ( $n = 1$ )).
- l) **Skin and soft tissue infections** ( $n = 5$ ): (bedsore infection ( $n = 3$ ); lymphadenitis ( $n = 1$ ); lymphangitis ( $n = 1$ )).
- m) **Hepatobiliary infections** ( $n = 4$ ): cholecystitis ( $n = 4$ ).
- n) **Fungal diseases** ( $n = 4$ ): hepato-splenic candidiasis ( $n = 2$ ), mucormycosis ( $n = 1$ ), fusariosis ( $n = 1$ ).
- o) **Periodontitis** ( $n = 1$ ).
- p) **Abscess formations** ( $n = 33$ )
- **Intra-abdominal abscesses** ( $n = 24$ ): liver ( $n = 7$ ), intraabdominal ( $n = 4$ ), renal ( $n = 4$ ), pericecal ( $n = 2$ ), amebic liver ( $n = 1$ ), diverticular ( $n = 1$ ), gall bladder ( $n = 1$ ), iliopsoas ( $n = 1$ ), perianal ( $n = 1$ ), uterine ( $n = 1$ ), subhepatic ( $n = 1$ ).
  - **CNS abscesses** ( $n = 3$ ): epidural brucellar ( $n = 1$ ), cerebral ( $n = 1$ ), epididymal ( $n = 1$ ).
  - **Pulmonary abscesses** ( $n = 2$ ): lungs ( $n = 2$ ).
  - **Other abscesses** ( $n = 4$ ): paravertebral ( $n = 2$ ), dental ( $n = 1$ ), subcutaneous ( $n = 1$ ).

**II. Neoplasms (n = 90)**

- Solid cancers (n = 27): lung (n = 8), colorectal (n = 3), adrenal gland (n = 3), neuroendocrine (n = 2), renal (n = 2), pancreas (n = 2), liver (n = 1), endometrium (n = 1), head and neck (n = 1), primary unknown (n = 1), prostate (n = 1), bone (n = 1), right atrium myxoma (n = 1).**
- Hematological malignancies (n = 60):**
- Lymphomas (n = 50): non-Hodgkin lymphoma (n = 25), Hodgkin lymphoma (n = 19), T-cell lymphoma (n = 4), anaplastic lymphoma (n = 2).
- Leukemias (n = 13): acute lymphocytic leukemia (n = 4), acute myeloid leukemia (n = 5), chronic myeloid leukemia (n = 2), multiple myeloma (n = 2).

**III. Collagen vascular disorders (n = 73)** Adult-onset Still's disease (n = 24), systemic lupus erythematosus (n = 8), polymyalgia rheumatica (n = 6), polyarteritis nodosa (n = 5), rheumatoid arthritis (n = 4), temporal arteritis (n = 4), large-vessel vasculitis (n = 3), reactive arthritis (n = 3), Behcet's disease (n = 2), myelitis (n = 1), familial Mediterranean fever (n = 1), giant cell arteritis (n = 1), gout arthritis (n = 1), Henoch Schoenlein purpura (n = 1), inflammatory myositis (n = 1), juvenile rheumatoid arthritis (n = 1), autoimmune hepatitis (n = 1), lupus nephropathy (n = 1), polymyositis (n = 1), seronegative arthropathy (n = 1), small vessel vasculitis (n = 1), Takayasu disease (n = 1), Wegener granulomatosis (n = 1).

**IV. Miscellaneous diseases** Thyroiditis (n = 12), histiocytosis (n = 7), Crohn's disease (n = 5), macrophage activation syndrome (n = 4), familial Mediterranean fever (n = 4), sarcoidosis (n = 3), embolic events (n = 3), hemophagocytic syndrome (n = 3), Kikuchi disease (n = 3), ulcerative colitis

(n = 2), aplastic anemia (n = 1), polycythemia vera (n = 1), autoimmune thyroiditis (n = 1), chronic fatigue syndrome (n = 1), cholecystitis (n = 1), cirrhosis (n = 1), primary biliary cirrhosis (n = 1), colon perforation (n = 1), Churg-Strauss syndrome (n = 1), endometriosis (n = 1), drug induced fever (n = 1), hepatic arterial thrombosis (n = 1), Horton disease (n = 1), neuroleptic malignant syndrome (n = 1).

**B. Invasive diagnostic procedures**

Overall, 201 (25.5%) patients were performed invasive sampling for FUO diagnosis. Invasive diagnostic sampling of FUO patients in accordance with the economic statuses are presented in Table 1. Diagnostic biopsies were done in 22 (29.7%) of HI country patients, in 90 (n = 21.6%) UMI country patients, and in 89 (29.9%) LMI country patients. There was a significant difference between the three economic statuses and performing biopsies (chi-square = 7.07,  $p = 0.029$ ).

**C. FUO and economic status**

Compared to residents of LI and LMI countries, having FUO among residents of HI and UMI countries does not significantly predict the diagnosis of infections ( $RR = 0.92$ , 95% CI: 0.80–1.05), and neoplasms ( $RR = 1.10$ , 95% CI: 0.73–1.66). Similarly, comparing HI vs UMI vs LMI countries, having FUO does not significantly predict the diagnosis of infection ( $\chi^2 = 0.5046$ ,  $p = 0.777$ ), and neoplasms ( $\chi^2 = 2.4270$ ,  $p = 0.297$ ). However, collagen vascular disorders ( $RR = 2.00$ , 95% CI: 1.19–3.38) were more likely to be reported from HI and UMI countries compared to LMI and LI countries. When HI vs UMI vs LMI countries were

**Table 1** Invasive diagnostic sampling in accordance with economic statuses

	HI (n = 74)	UMI (n = 416)	LMI (n = 297)	LI (n = 1)
Lymph node bx (n = 188)	21 (28.4%)	85 (20.4%)	82 (27.6%)	
Bone marrow bx (n = 57)	9 (4.7%)	28 (6.7%)	20 (6.7%)	
Liver bx (n = 13)		3 (0.7%)	10 (3.4%)	
Colon bx (n = 11)	3 (4.1%)	5 (1.2%)	3 (1%)	
Skin bx (n = 11)	1 (1.4%)	4 (1%)	6 (2%)	
Temporal artery bx (n = 7)		3 (0.7%)	4 (1.3%)	
Kidney bx (n = 5)			5 (1.7%)	
Lung bx (n = 5)		2 (0.5%)	3 (1%)	
Pleura bx (n = 2)		1 (0.2%)		
Thyroid bx (n = 2)		1 (0.2%)	1 (0.3%)	
Prostate bx (n = 1)			1 (0.3%)	
Ileum bx (n = 1)		1 (0.2%)		
Gastric bx (n = 1)	1 (1.4%)			

HI high income, LI low-income, LMI low-middle income, UMI upper-middle income, Bx biopsy

compared, FOU significantly predicts the diagnosis of collagen vascular disorders ( $\chi^2 = 7.5526$ ,  $p = 0.023$ ).

#### D. Clinical FOU associations

Compared to non-late elderly age group, having FOU among the late elderly population does not significantly predict the diagnoses of infection ( $RR = 1.11$ , 95% CI:

0.85–1.45), neoplasms ( $RR = 1.43$ , 95% CI: 0.70–2.89), and collagen vascular disorders ( $RR = 0.48$ , 95% CI: 0.12–1.88) (Tables 2 and 3). The relationships between inflammatory markers and FOU diagnoses are shown in Table 4; the outcomes of FOU in accordance with economic statuses are presented in Table 5. We could not disclose any significant difference for death attributable to FOU when HI vs UMI vs LMI countries were compared ( $\chi^2 = 1.62$ ,  $p = 0.440$ ). Similarly, the mean duration of days

**Table 2** FOU categories and economic status

Diagnoses	High-income countries (n = 74)	Upper-middle income countries (n = 416)	Low-middle income countries (n = 297)	Low income countries (n = 1)
Infections (n = 407)	36	209	162	0
Neoplasms (n = 90)	5	53	32	0
CVD (n = 73)	7	49	17	0
Undiagnosed (n = 158)	14	79	64	1
Other (n = 60)	12	26	22	0

CVD collagen vascular disorders

**Table 3** Comparison of FOU distributions in accordance with the economic statuses

	Etiology of FOU		Relative risk (95% CI)	Pearson chi-square $\chi^2$	p-value
	Infections	Non-infections			
HI/UMI	245/407	245/381	0.92 (0.80–1.05)	1.41	0.2347
LMI/LI	162/407	136/381			
	Neoplasms	Non-neoplasms			
HI/UMI	58/90	432/698	1.10 (0.73–1.66)	0.22	0.633
LMI/LI	32/90	266/698			
	CVDs	Non-CVDs			
HI/UMI	56/73	434/715	2.00 (1.19–3.38)	7.22	0.0072
LMI/LI	17/73	281/715			
	Undiagnosed	All Others			
HI/UMI	93/158	397/630	0.87 (0.65–1.15)	0.93	0.3355
LMI/LI	65/158	233/630			
Aging and FOU					
	Infections	Non—infections			
Late elderly	25/407	19/381	1.11 (0.85–1.45)	0.50	0.4802
Non-late elderly	382/407	362/381			
	Neoplasms	Non-neoplasms			
Late elderly	7/90	37/699	1.43 (0.70–2.89)	0.93	0.3355
Non-late elderly	83/90	661/699			
	CVDs	Non-CVDs			
Late elderly	2/73	42/715	0.48 (0.12–1.88)	1.23	0.2666
Non-late elderly	71/73	673/715			
	Undiagnosed	All Others			
Late elderly	9/158	35/630	1.02 (0.56–1.86)	0.00	0.9451
Non-late elderly	149/158	595/630			

CVD collagen vascular disorders, HI high income, LI low-income, LMI low-middle income, UMI upper-middle income

**Table 4** Examining for the relationships between inflammatory markers and FUO diagnoses

	Infections	Neoplasms	CVD	Undiagnosed	Other diseases	F test	<i>p</i>
CRP (mg/l)	<i>n</i> = 392, 120.9 ± 108.6	<i>n</i> = 88, 129.2 ± 103.7	<i>n</i> = 71, 108.4 ± 84.1	<i>n</i> = 148, 120.6 ± 95.6	<i>n</i> = 61, 108.5 ± 121.5	0.58	0.6762
WBC (/μL)	<i>n</i> = 406, 9868.0 ± 6807.0	<i>n</i> = 90, 7602.3 ± 6183.9	<i>n</i> = 73, 11,129.8 ± 5610.1	<i>n</i> = 158, 8804.9 ± 5833.9	<i>n</i> = 60, 11,012.7 ± 21,297.9	2.69	<b>0.0300</b>
ESR (mm/h)	<i>n</i> = 349, 66.06 ± 52.49	<i>n</i> = 80, 66.9 ± 35.7	<i>n</i> = 70, 8.41 ± 33.5	<i>n</i> = 125, 61.8 ± 39.2	<i>n</i> = 54, 60.0 ± 39.1	1.59	0.1765
Ferritin (ng/ml)	<i>n</i> = 185, 875.2 ± 2574.2	<i>n</i> = 61, 2102.9 ± 4191.4	<i>n</i> = 63, 2788.5 ± 6451.3	<i>n</i> = 72, 1815.1 ± 4195.2	<i>n</i> = 36, 3477.4 ± 8707.5	3.82	<b>0.0046</b>
Cr (mg/dl)	<i>n</i> = 402, 1.0 ± 0.6	<i>n</i> = 87, 0.9 ± 0.3	<i>n</i> = 72, 0.8 ± 0.5	<i>n</i> = 153, 0.9 ± 0.8	<i>n</i> = 59, 0.9 ± 0.4	1.18	0.3195

CRP C-reactive protein, PCT procalcitonin, WBC white blood cell count, ESR erythrocyte sedimentation rate, Cr creatinine, CVD collagen vascular disorders

until diagnosis after hospitalization did not differ across the economic statuses ( $p = 0.9663$ ).

## Discussion

FUO cases are a critical group of patients with 6.3% attributable mortality according to our data. Traditionally numerous causes of classic FUO fall within five categories: infections, neoplasms, connective tissue diseases, miscellaneous other disorders, and undiagnosed illnesses [10]. Infections had long been the leading causes of classical FUO [1, 2]. Accordingly, febrile conditions are the optimum timings of consultations from infectious diseases departments and increase the workloads of these services [11]. In recent FUO papers from LMI countries, infections ranged from 43 to 63% establishing the majority of FUO cases while neoplasms comprised 1–22%, and collagen vascular disorders made up 13–30%, miscellaneous diseases comprised 2–14%, and undiagnosed FUO patients had a share of 2–12% [12–15]. The distributions of FUO diagnoses in FUO reports from richer (UMI and HI) countries were infections 15–49%, neoplasms 7–18%, collagen vascular disorders 19–47%, miscellaneous diseases 1–13%, and undiagnosed 8–30% [16–23]. Thus, there has been an understanding that FUO due to infections was most likely to be related to countries with limited resources, and developed or richer countries have predilections for noninfectious subsets of FUO diagnoses like neoplasms or collagen vascular disorders [2, 24]. However, we could not disclose such relationships for the entire FUO groups other than collagen vascular disorders, which were more frequently reported from richer countries. Although it appears that the disseminated knowledge and improving health infrastructures worldwide have a tendency to uniform the diagnoses for infections and neoplasms, the collagen vascular disorders were not equally identified and less commonly detected in country groups with lower economic incomes. Since our study pooled relatively new FUO patients followed in the last 5 years, this datum appears to be the new trend in the context of FUO diagnoses. In addition, either the duration of diagnosis for FUO cases or patients without diagnosis did not differ between the richer countries and those with the limited resources showing a degree of standardization.

Actually, economic welfare may not always be translated as a high Human Development Index, which is a statistic composite index of life expectancy, education, and per capita income [25]. In addition, wide geographical distribution of the participating centers may have resulted in diverse epidemiological exposures. Hence, other developmental parameters may disclose variations in FUO epidemiology, rather than the economic status. Accordingly, there had been

**Table 5** FUO outcomes in accordance with economic statuses

	HI ( <i>n</i> = 74)	UMI ( <i>n</i> = 416)	LMI ( <i>n</i> = 297)	LI ( <i>n</i> = 1)
Died; attributed to FUO ( <i>n</i> = 50, 6.3%)	2	29	19	0
Died; NOT attributable to FUO ( <i>n</i> = 17, 2.1%)	1	11	5	0
Transferred to another unit ( <i>n</i> = 71, 9%)	5	36	29	1
Still at hospital ( <i>n</i> = 7, 0.9%)	0	2	5	0
Discharged with cure ( <i>n</i> = 386, 49%)	47	198	141	0
Discharged with sequelae ( <i>n</i> = 129, 16.4%)	17	36	76	0
Discharged as she/he is ( <i>n</i> = 120, 15.2%)	2	97	21	0
No information ( <i>n</i> = 8, 1%)	0	7	1	0

CVD collagen vascular disease, HI high income, LI low-income, LMI low-middle income, UMI upper-middle income

an understanding that infections were less common in the elderly population compared to non-elderly [10]. But it was not the case in this study. Moreover, attributable FUO mortality was not significantly different between richer countries and those with limited resources. There seemed to be a uniformity in the distribution and outcomes of FUO diagnoses in the participating centers, and the delayed diagnosis is likely to be due to subtle nature of FUO causes rather than the economic prosperity.

In this study, half of FUO diagnoses were infections, which can have fatal outcomes when timely and rational antimicrobial treatment are not provided [26]. Although infections as the agents of FUO tend to vary in incidence according to locale, the leading community-acquired infections for classical FUO were tuberculosis, brucellosis, rickettsiosis, HIV infection, and typhoid fever in this survey. Tuberculosis has long been one of the common causes of FUO [24, 27] and brucellosis is the most frequent zoonotic infection worldwide [28] so that they were two of the common infections causing FUO. Since zoonoses are a heterogeneous group of syndromes and cardiovascular infections are a uniform clinical entity, we can say that cardiovascular infections are the most common infectious syndromes among our FUO cases. We found that native valve endocarditis in particular, comprising more than two thirds of cardiovascular infections in routine medical practice [29], was the most common infectious syndromes among our FUO cases. The other common cause of FUO “bacteremia of unidentified origin” in this study may represent cardiovascular infections where the diagnosis could not be well established, too. Hence, any type of bacteremia in a FUO patient should warrant investigation for cardiovascular infections. In addition, pulmonary infections with atypical patterns, urogenital infections, and central nervous system infections with rare presentations were the other common syndromic infectious FUO presentations. Abscesses, intraabdominal locations as the most prominent, were not rare suppurative foci compelling the need of well-established radiological diagnosis in this study. Since infections imposes serious challenges and high mortality when untreated [26], early diagnosis in which even

invasive procedures are shown to be needed in one-fourth of FUO patients in our study. Interestingly, biopsies were performed more commonly in LMI countries according to our data.

Returning travelers is a certain subset of patients in FUO series in which malaria, typhoid fever, and acute HIV infection were commonly recorded [10]. In routine medical practice, intestinal and respiratory infections including pneumonia and tuberculosis followed by malaria, visceral leishmaniasis, and hemorrhagic fevers are the common etiologies in severely infected travelers and migrants [3, 30]. We detected malaria only as the causes of FUO in this subgroup of patient population. This is the most common mosquito-borne disease with major epidemiological outbreaks in the equatorial, tropical, and subtropical climate zones of mainly in Africa and to a lesser extent in Asia, Central America, and Southern America. Another potential reason for FUO in this group of persons could be lymphatic filariasis (elephantiasis) which is endemic to Africa. In fact, the reasons for FUO in returning travelers are too many as with other people who have not had a trip. Here, too, the potential and most likely cause is an infectious disease caused by bacteria or parasites. Therefore, in FUO patients coming from countries with a high prevalence of any infection, it is appropriate to investigate the most common infections found in the country they have visited. The patient’s contact history for any type of infected patients, skin rashes, bites including vectors, water, and food consumption history should be questioned in detail.

The next common FUO category comprises neoplastic diseases, most commonly hematological malignancies including lymphomas and leukemias followed by solid cancers. The third leading cause of classical FUO is collagen vascular disorders where adult-onset Still’s disease is the most common followed by systemic lupus erythematosus, polymyalgia rheumatica, and polyarteritis nodosa in this study. When the inflammatory markers are compared among the diagnostic categories, ferritin and leucocyte count was significantly higher in the FUO patients without



an established diagnosis, and this result may likely to stress the presence of non-infectious inflammatory diseases or collagen vascular disorders in patients without a diagnosis. Histopathologic examination of tissues, which appears to be the last bullet for definitive diagnosis, can provide a final diagnosis in FUO patients in fewer than half of cases[31], and thus one fourth of our patients were performed histopathological examination to reach a definitive diagnosis.

The current research has some limitations that need to be addressed. First, the study has a retrospective design, although we included only patients followed in the last 5 years. Second, the medical centers participating in this survey have heterogeneous diagnostic capacities due to the different economic developments of their countries. Third, because of heterogeneity of FUO cases, the number of patients included in the study is very low for particular subsets of diagnoses. Finally, the numbers of patients included from each country were variable, and thus, the patients may not be representative of all patients for FUO in their particular countries. However, as a strength, we categorized and analyzed the patients according to the economic level of the countries they belong. Despite the aforementioned limitations, this work represents the first research on patients with FUO from countries with different economic stages of development.

In conclusion, the diagnosis of FUO should be tailored according to the common disorders causing FUO. In this regard, it is a serious difficulty to implement diagnostic protocols for patients with FUO and a potential FUO protocol cannot cover all possible causes of this medical problem. Our results and data from other studies show that regardless of the economic development of the countries, the leading causes of FUO are similar and still conventional. Hence, the clinicians worldwide should be aware of the current FUO epidemiology, which is unaffected from economic status to ease clinical decision making.

**Author contribution** Hakan Erdem: conceptualization, data curation, formal analysis, investigation, methodology, visualization, writing, and supervision. Magdalena Baymakova: conceptualization, formal analysis, investigation, methodology, and writing. Sevil Alkan: conceptualization, data curation, and investigation. Farouq Dayyab: conceptualization, statistical analysis, and writing. Jordi Rello: conceptualization, writing and editing, and supervision. All other authors agreed the design of the study, collected and submitted the data of patients followed/treated in their centers, reviewed the paper, and obtained IRBs, if necessary. All authors have read and agreed to the submitted version of the manuscript.

**Data availability** It will available on request.

**Code availability** None applicable.

## Declarations

**Ethics approval** The ethical approval of the study was taken from The Ethical Counsel of Istanbul Medeniyet University, Faculty of Medicine, Istanbul (4 August 2021/0411).

**Consent to participate** None applicable.

**Consent for publication** None applicable.

**Conflict of interest** The authors declare no competing interests.

## References

- Haidar G, Singh N (2022) Fever of unknown origin. *N Engl J Med* 386:463–477. <https://doi.org/10.1016/B978-0-323-05405-8.00056-5>
- Kucukardali Y, Oncul O, Cavuslu S, Danaci M, Calangu S, Erdem H et al (2008) The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study. *Int J Infect Dis* 12:71–79. <https://doi.org/10.1016/j.ijid.2007.04.013>
- Erdem H, Ak O, Elaldi N, Demirdal T, Hargreaves S, Nemli SA et al (2016) Infections in travellers returning to Turkey from the Arabian peninsula: a retrospective cross-sectional multicenter study. *Eur J Clin Microbiol Infect Dis* 35:903–910. <https://doi.org/10.1007/s10096-016-2614-z>
- Korzeniewski K, Gawel B, Krankowska D, Wasilczuk K (2015) Fever of unknown origin in returning travellers. *Int Marit Health* 66:77–83. <https://doi.org/10.5603/IMH.2015.0019>
- Durack DT, Street AC (1991) Fever of unknown origin—reexamined and redefined. *Curr Clin Top Infect Dis* 11:35–51
- Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M (2017) Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. *Lancet* 389:1323–1335. [https://doi.org/10.1016/S0140-6736\(16\)32381-9](https://doi.org/10.1016/S0140-6736(16)32381-9)
- Prasad S, Sung B, Aggarwal BB (2012) Age-associated chronic diseases require age-old medicine: role of chronic inflammation. *Prev Med (Baltim)* 54:S29–37. <https://doi.org/10.1016/j.ypmed.2011.11.011>
- Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M (2006) Reviewing the definition of “elderly.” *Geriatr Gerontol Int* 6:149–158. <https://doi.org/10.1111/j.1447-0594.2006.00341.x>
- World Bank Country and Lending Groups. Available at <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>. Accessed 10 May 2022
- Wright W (2020) Fever of Unknown Origin. In: Bennett JE, Dolin R, Blaser Martin J (eds) *Mandell, Douglas, and Bennett’s principles and practice of infectious diseases*. Elsevier Co, Philadelphia, pp 790–803
- Erdem H, Kurtaran B, Arun O, Yılmaz H, Çelebi B, Özkaya HD et al (2012) The place and the efficacy of infectious disease consultations in the hospitals. *Infect Dis Clin Pract* 20:131–136. <https://doi.org/10.1097/IPC.0b013e31823c4b25>
- Mahmood K, Akhtar T, Naeem M, Talib A, Haider I (2013) Siraj-Us-Salikeen Fever of unknown origin at a tertiary care teaching hospital in Pakistan. *Southeast Asian J Trop Med Public Health* 44:503–11
- Kabapy AF, Kotkat AM, Shatat HZ, El-Wahab A (2016) Clinico-epidemiological profile of fever of unknown origin in an Egyptian setting: a hospital-based study (2009–2010). *J Infect Dev Ctries* 10:030–042. <https://doi.org/10.3855/jidc.7198>
- Rupali P, Garg D, Viggweswarupu S, Sudarsanam T, Jayaseelan V, Abraham O (2019) Etiology of classic fever of unknown origin (FUO) among immunocompetent Indian adults. *J Assoc Physicians India* 67(1):21–26
- Pannu AK, Golla R, Kumari S, Suri V, Gupta P, Kumar R (2021) Aetiology of pyrexia of unknown origin in north India. *Trop Doct* 1(51):34–40. <https://doi.org/10.1177/0049475520947907>
- Letertre S, Fesler P, Zerkowski L, Picot M-C, Ribstein J, Guilpain P et al (2021) Clinical medicine place of the 18 F-FDG-PET/CT in

- the diagnostic workup in patients with classical fever of unknown origin (FUO). *J Clin Med*. <https://doi.org/10.3390/jcm10173831>
17. Shang J, Yan L, Du L, Liang L, Zhou Q, Liang T et al (2017) Recent trends in the distribution of causative diseases of fever of unknown origin. *Wien Klin Wochenschr* 129:201–207. <https://doi.org/10.1007/s00508-016-1159-6>
  18. Naito T, Tanei M, Ikeda N, Ishii T, Suzuki T, Morita H et al (2019) Key diagnostic characteristics of fever of unknown origin in Japanese patients: a prospective multicentre study. *BMJ* 9:e032059. <https://doi.org/10.1136/bmjopen-2019-032059>
  19. Bosilkovski M, Dimzova M, Cvetkova M, Poposki K, Spasovska K, Vidinic I (2019) The changing pattern of fever of unknown origin in the Republic of North Macedonia. *Rom J Intern Med* 57:248–253
  20. Zhou G, Zhou Y, Zhong C, Ye H, Liu Z, Liu Y et al (2020) Retrospective analysis of 1,641 cases of classic fever of unknown origin. *Ann Transl Med* 8:690. <https://doi.org/10.21037/atm-20-3875>
  21. Yenilmez E, Kakalicoglu D, Bozkurt F, Filiz M, Akkol Camurcu A, Damar Midik EO et al (2021) Fever of unknown origin (FUO) on a land on cross-roads between Asia and Europa; a multicentre study from Turkey. *Int J Clin Pract* 75:1–12. <https://doi.org/10.1111/ijcp.14138>
  22. Buchrits S, Gafter-Gvili A, Eynath Y, Bernstine H, Guz D, Avni T (2021) The yield of F18 FDG PET-CT for the investigation of fever of unknown origin, compared with diagnostic CT. *Eur J Intern Med* 93:50–56. <https://doi.org/10.1016/j.ejim.2021.07.014>
  23. Schönau V, Vogel K, Englbrecht M, Wacker J, Schmidt D, Manger B et al (2018) The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. *Ann Rheum Dis* 77:70–77. <https://doi.org/10.1136/annrheumdis-2017-211687>
  24. Wright WF, Yenokyan G, Simner PJ, Carroll KC, Auwaerter PG (2021) Geographic variation of infectious disease diagnoses among patients with fever of unknown origin: a systematic review and meta-analysis. *Open Forum Infect Dis* 9:151. <https://doi.org/10.1093/ofid/ofac151>
  25. Human Development Index [Internet]. Wikipedia [cited 2022 23] [https://en.wikipedia.org/wiki/Human\\_Development\\_Index](https://en.wikipedia.org/wiki/Human_Development_Index)
  26. Erdem H, Tetik A, Arun O, Besirbellioglu BA, Coskun O, Eyigun CP (2011) War and infection in the pre-antibiotic era: the Third Ottoman Army in 1915. *Scand J Infect Dis* 43:690–695. <https://doi.org/10.3109/00365548.2011.577801>
  27. Erdem H, Akova M (2012) Leading infectious diseases problems in Turkey. *Clin Microbiol Infect* 18:1056–1067. <https://doi.org/10.1111/1469-0691.12000>
  28. Saydam FN, Erdem H, Ankarali H, El-Arab Ramadan ME, El-Sayed NM, Civljak R et al (2021) Vector-borne and zoonotic infections and their relationships with regional Asia and socio-economic statuses: an ID-IRI survey in 24 countries of Europe, Africa and Asia. *Travel Med Infect Dis* 44:102174. <https://doi.org/10.1016/j.tmaid.2021.102174>
  29. Erdem H, Puca E, Ruch Y, Santos L, Ghanem-zoubi N, Argemi X (2019) Portraying infective endocarditis: results of multinational ID-IRI study. *Eur J Clin Microbiol Infect Dis* 38:1753–1763
  30. Alp E, Erdem H, Rello J (2016) Management of septic shock and severe infections in migrants and returning travelers requiring critical care. *Eur J Clin Microbiol Infect Dis* 35:527–533. <https://doi.org/10.1007/s10096-016-2575-2>
  31. Arnow PM, Flaherty JP (1997) Fever of unknown origin. *Lancet* 350:575–580. [https://doi.org/10.1016/S0140-6736\(97\)07061-X](https://doi.org/10.1016/S0140-6736(97)07061-X)

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

## Authors and Affiliations

Hakan Erdem<sup>1</sup>  · Magdalena Baymakova<sup>2</sup> · Sevil Alkan<sup>3</sup> · Amel Letaief<sup>4</sup> · Wissal Ben Yahia<sup>4</sup> · Farouq Dayyab<sup>5</sup> · Entela Kolovani<sup>6</sup> · Svtjetlana Grgic<sup>7</sup> · Federica Cosentino<sup>8</sup> · Imran Hasanoglu<sup>9</sup> · Reham Khedr<sup>10</sup> · Andrea Marino<sup>8</sup> · Abdullah Umut Pekok<sup>11</sup> · Fatma Eser<sup>9</sup> · Jurica Arapovic<sup>7</sup> · Hatice Rahmet Guner<sup>9</sup> · Ionela-Larisa Miftode<sup>12</sup> · Kostadin Poposki<sup>13</sup> · Gamze Sanlidag<sup>14</sup> · Alper Tahmaz<sup>15</sup> · Oguz Resat Sipahi<sup>14</sup> · Egidia Gabriela Miftode<sup>12</sup> · Serkan Oncu<sup>16</sup> · Meliha Cagla-Sonmezer<sup>17</sup> · Syam Kumar Addepalli<sup>18</sup> · Ilad Alavi Darazam<sup>19</sup> · Hema Prakash Kumari<sup>20</sup> · Meliha Meriç Koc<sup>21</sup> · Meela Ranjith Kumar<sup>22</sup> · Suresh Babu Sayana<sup>23</sup> · Ahmed Ashraf Wegdan<sup>24</sup> · Fatma Amer<sup>25</sup> · Mehmet Resat Ceylan<sup>26</sup> · Amani El-Kholy<sup>27</sup> · Taylan Onder<sup>3</sup> · Hamed Azhdari Tehrani<sup>28</sup> · Atousa Hakamifard<sup>19</sup> · Bircan Kayaaslan<sup>9</sup> · Ghaydaa Shehata<sup>29</sup> · Hulya Caskurlu<sup>30</sup> · Nagwa Mostafa El-Sayed<sup>31</sup> · Seyed Erfan Mortazavi<sup>19</sup> · Mohammad Pourali<sup>19</sup> · Umran Elbahr<sup>32</sup> · Sholpan Kulzhanova<sup>33</sup> · Tarkan Yetisyigit<sup>34</sup> · Sahar Ahmed Saad<sup>35</sup> · Yasemin Cag<sup>30</sup> · Gulden Eser-Karlidag<sup>36</sup> · Natalia Pshenichnaya<sup>37</sup> · Maya Belitova<sup>38</sup> · Nasim Akhtar<sup>39</sup> · Fahad Al-Majid<sup>40</sup> · Muge Ayhan<sup>9</sup> · Mumtaz Ali Khan<sup>41</sup> · Massimiliano Lanzafame<sup>42</sup> · Mateja Jankovic Makek<sup>43</sup> · Emmanuel Nsutebu<sup>44</sup> · Antonio Cascio<sup>45</sup> · Emine Kubra Dindar-Demiray<sup>46</sup> · Emine Unal Evren<sup>47</sup> · Rama Kalas<sup>48</sup> · Ayşe Kaya Kalem<sup>9</sup> · Rusmir Baljić<sup>49</sup> · Aamer Ikram<sup>50</sup> · Selcuk Kaya<sup>51</sup> · Anna Liskova<sup>52</sup> · Balint Gergely Szabo<sup>53</sup> · Bilal Ahmad Rahimi<sup>54</sup> · Esmeray Mutlu-Yilmaz<sup>55</sup> · Alper Sener<sup>3</sup> · Jordi Rello<sup>56,57</sup>

<sup>1</sup> Department of Infectious Diseases & Clinical Microbiology, Gulhane School of Medicine, Turkish Health Sciences University, Ankara, Turkey

<sup>2</sup> Department of Infectious Diseases, Military Medical Academy, Sofia, Bulgaria

<sup>3</sup> Department of Infectious Diseases and Clinical Microbiology, Onsekiz Mart University School of Medicine, Canakkale, Turkey

<sup>4</sup> Department of Infectious Diseases, Farhat Hached University Hospital, Ibn El Jazzar Medical School, University of Sousse, Sousse, Tunisia

<sup>5</sup> Department of Internal Medicine, King Hamad University Hospital, Al Sayh, Manama, Bahrain

<sup>6</sup> Infectious Disease Clinic, University Hospital Center 'Mother Theresa', Tirana, Albania

<sup>7</sup> Department of Infectious Diseases, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina

<sup>8</sup> Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, ARNAS Garibaldi Hospital, University of Catania, Catania, Italy

<sup>9</sup> Department of Infectious Diseases & Clinical Microbiology, Ankara City Hospital, Ankara, Turkey

<sup>10</sup> Department of Pediatric Oncology, National Cancer Institute - Cairo University, Children Cancer Hospital Egypt, Cairo, Egypt

<sup>11</sup> VM Medical Park, Pendik Hospital, Istanbul, Turkey

<sup>12</sup> St. Parascheva Clinical Hospital of Infectious Diseases, Iasi, Romania

<sup>13</sup> Faculty of Medicine, University Clinic for Infectious Diseases and Febrile Conditions, Skopje, Republic of North Macedonia

<sup>14</sup> Department of Infectious Diseases & Clinical Microbiology, Ege School of Medicine, Izmir, Turkey

<sup>15</sup> Department of Infectious Diseases & Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Turkey

<sup>16</sup> Department of Infectious Diseases & Clinical Microbiology, School of Medicine, Adnan Menderes University, Aydin, Turkey

<sup>17</sup> Department of Infectious Diseases & Clinical Microbiology, Hacettepe School of Medicine, Hacettepe University, Ankara, Turkey

<sup>18</sup> Department of Pharmacology, GITAM Institute of Medical Sciences and Research, Visakhapatnam, Andhra Pradesh, India

<sup>19</sup> Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>20</sup> Department of Microbiology, GITAM Institute of Medical Sciences and Research, Visakhapatnam, Andhra Pradesh, India

<sup>21</sup> Department of Infectious Diseases & Clinical Microbiology, School of Medicine, Bezmialem Vakif University, Istanbul, Turkey

<sup>22</sup> Department of Pharmacology, Government Medical College & Government General Hospital, Suryapet, Telangana, India

<sup>23</sup> Department of Pharmacology, Government Medical College, Suryapet, Telangana, India

<sup>24</sup> Department of Medical Microbiology and Immunology, Faculty of Medicine, Fayoum University, Fayoum, Egypt

<sup>25</sup> Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>26</sup> Department of Infectious Diseases & Clinical Microbiology, School of Medicine, Harran University, Sanliurfa, Turkey

<sup>27</sup> Department of Clinical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt

<sup>28</sup> Department of Hematology and Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>29</sup> Department of Neurology, Assiut University, Assiut, Egypt

- <sup>30</sup> Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
- <sup>31</sup> Medical Parasitology Department, Research Institute of Ophthalmology, Giza, Egypt
- <sup>32</sup> Department of Infectious Diseases, Bahrain Oncology Center, King Hamad University Hospital, Busaiteen, Bahrain
- <sup>33</sup> Department of Infectious Diseases, Astana Medical University, Nur-Sultan, Kazakhstan
- <sup>34</sup> Department of Oncology, Bahrain Oncology Center, King Hamad University Hospital, Busaiteen, Bahrain
- <sup>35</sup> Department of Rheumatology, King Hamad University Hospital, Al Sayh, Bahrain
- <sup>36</sup> Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Elazig Fethi Sekin City Hospital, Elazig, Turkey
- <sup>37</sup> Central Research Institute of Epidemiology, Moscow, Russia
- <sup>38</sup> Medical University of Sofia, Sofia, Bulgaria
- <sup>39</sup> Pakistan Institute of Medical Sciences, Islamabad G-8/3, Pakistan
- <sup>40</sup> Department of Medicine, Infectious Diseases Division, King Saud University, Riyadh, Saudi Arabia
- <sup>41</sup> National Institute of Health, Islamabad, Pakistan
- <sup>42</sup> Unit of Infectious Diseases, Santa Chiara Hospital, Trento, Italy
- <sup>43</sup> School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia
- <sup>44</sup> Tropical and Infectious Diseases Division, Sheikh Shakhboub Medical City, Abu Dhabi, United Arab Emirates
- <sup>45</sup> Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) - Infectious Disease Unit, Policlinico 'P. Giaccone', University of Palermo, Palermo, Italy
- <sup>46</sup> Department of Infectious Diseases and Clinical Microbiology, Bitlis Public Hospital, Bitlis, Turkey
- <sup>47</sup> Department of Infectious Diseases and Clinical Microbiology, School of Medicine, University of Kyrenia, Kyrenia, Cyprus
- <sup>48</sup> Internal Medicine Division, Sheikh Shakhboub Medical City, Abu Dhabi, United Arab Emirates
- <sup>49</sup> KCU Sarajevo, Sarajevo, Bosnia and Herzegovina
- <sup>50</sup> National Institutes of Health, Islamabad, Pakistan
- <sup>51</sup> Department of Infectious Diseases and Clinical Microbiology, Karadeniz Technical University School of Medicine, Trabzon, Turkey
- <sup>52</sup> Hospital Nitra, St. Elisabeth University of Health Care and Social Work, Bratislava, Slovak Republic
- <sup>53</sup> South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary
- <sup>54</sup> Department of Infectious Diseases, Kandahar University Medical Faculty, Teaching Hospital, Kandahar, Afghanistan
- <sup>55</sup> Department of Infectious Diseases & Clinical Microbiology, Samsun Training and Research Hospital, Samsun, Turkey
- <sup>56</sup> Clinical Research and Epidemiology in Pneumonia and Sepsis, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain
- <sup>57</sup> Clinical Research, CHRU Nîmes, Nîmes, France

## Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)